Glenmark's Monroe facility classified as voluntary action indicated by USFDA

Glenmark Pharmaceuticals has received a positive report from the US health regulator. The company's manufacturing facility in Monroe, North Carolina, has been classified as Voluntary Action Indicated. This development means the facility can now restart commercial manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTzZfPs
via IFTTT